Exclusive to WSJ News | Pfizer in advanced talks to buy global blood therapies for approximately $5 billion


Pfizer is in advanced talks to buy Global Blood Therapy the maker of a recently approved drug for sickle cell disease, for about $5 billion, in the drug giant’s latest step to bolster its portfolio and pipeline.

Pfizer is aiming to close a deal for GBT in the coming days, according to people familiar with the matter. The situation is still fluid and other suitors are still in the mix, some people said. GBT will announce its second quarter results on Monday.

See also  Intel shares plunge more than 10% after broad earnings misses that CEO says 'reflect our own execution problems'



Please enter your comment!
Please enter your name here